Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
337 Leser
Artikel bewerten:
(1)

Blood Collection Tubes for Liquid Biopsy Sales Set to Grow at 12% through 2021: Fact.MR

NEW YORK, March 11, 2021 /PRNewswire/ -- Fact.MR is conducting an ongoing research study on the blood collection tubes for liquid biopsy market. As per its findings, a positive growth outlook is expected for 2021, primarily underpinned by increasing technological advancements and increasing R&D activities from the government. Growth prospects for the upcoming decade are also optimistic, registering a noteworthy expansion rate until 2031.

FactMR Logo

According to Fact.MR, the market is poised to benefit immensely from the rising usage of CTCs and ctDNA for liquid biopsy applications. According to National Center for Health Statistics, in 2021, 1.8 million new cancer cases are projected to occur in the U.S., surging the sales for blood collection tubes for liquid biopsy.

According to World Health Organization (WHO), in 2021 stated that breast cancer has now overtaken as the most commonly diagnosed cancer globally. In 2020, over 19.3 million breast cancer cases were registered worldwide. Hence, uptake of blood collection tubes for liquid biopsy is likely to surge manifold.

"Technological advancements are aiding the blood collection tubes for liquid biopsy manufacturers, while initiatives undertaken by government are spurring the growth of the market," says a Fact.MR analyst.

For more Insights into the Market, Request a Sample of this Report

https://www.factmr.com/connectus/sample?flag=S&rep_id=4495

Key Takeaways

  • By product, CTCs and ccfDNA to acquire high priority owing to the increasing chronic diseases such as prostate and ovarian cancer
  • Genetic Diagnostic Labs to remain primary end user for blood collection tubes
  • Lack of skilled professionals to be a major restraint for the growth of blood collection tubes for liquid biopsy
  • The U.S. to remain the most lucrative market through 2021 and beyond
  • Germany is spearheading growth registered in Europe
  • Remarkable surge in the sales for blood collection tubes for liquid biopsy driving growth in France
  • India to emerge as a promising blood collection tubes for liquid biopsy hub, owing to the rising breast cancer cases
  • By material, glass is expected to foster demand at a significant CAGR of nearly 10%

Competitive Landscape

Roche, Streck, Preanalytix, Norgen Biotek, Biocept, Biometrica, and INVITEK MOLECULAR GMBH (Nuvisan GmbH/ Stratec Group) are some of the key companies that are profiled by Fact.MR. Leveraging strategic partnerships and new product launches constitutes an important part of the expansion strategy for aforementioned players.

For instance, in March 2021, Roche's Actemra/RoActemra becomes the first biologic therapy approved by FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease that's been affecting 2.5 million people globally.

Also, in November 2020, Streck announced the launch of Zulu RT, a rapid, modular qPCR instrument capable of performing four independent experiments simultaneously.

Get Customization on this Report for Specific Country

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4495

More Valuable Insights on Blood collection tubes for liquid biopsy Market

Fact.MR, in its new offering, presents a detailed analysis of the global blood collection tubes for liquid biopsy market. The study divulges essential insights on the blood collection tubes for liquid biopsy market on the basis of product (CcfDNA tubes, ccfDNA isolation kits, CfRNA tubes, ccfRNA isolation kits, CTC tubes, gDNA tubes, gDNA isolation kits, intracellular RNA tubes, intracellular RNA kits, and NIPT), material (glass and plastic), application (IVD and research), end-user (R&D centers, genetic diagnostic labs, and conventional diagnostic centers), and regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

Key Questions Covered in the Report

  • Which is the most lucrative market for blood collection tubes for liquid biopsy?
  • Which are some of the key companies offering blood collection tubes for liquid biopsy?
  • Which product remains dominant in the blood collection tubes for liquid biopsy market?
  • What is the impact of regulation on blood collection tubes for liquid biopsy market?
  • Why is demand in China rising for blood collection tubes?
  • What is the impact of Covid-19 on blood collection tubes for liquid biopsy market?

Request more information about Report Methodology

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4495

Explore Fact.MR's Coverage on the Healthcare Domain

Navigated Biopsy Needles Market: The global navigated biopsy needles market report published by Fact.MR sheds an insight on the prominent growth dynamics, including possible drivers, opportunities and challenges, expected to prevail across the landscape for the upcoming decade. A detailed insight regarding key geographies and prominent manufacturers has been embedded in this report.

Breast biopsy localization wire Market: Explore Fact.MR's breast biopsy localization wire market research report, offering a detailed study on multiple market trends for the present and upcoming decade. The study entails analyses about the prominent growth trends present across key geographies and major segments, along with information about key manufacturers operating within the landscape.

Bone Biopsy Systems Market: The global Bone Biopsy Systems market report by Fact.MR delivers a detailed analysis on the strategies and competitive landscape for the upcoming period. The key players' market share data provided by the report given you a detailed insights on the shortcomings and forthcomings of the market for the forecast period.

About Fact.MR

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we'll be an able research partner.

Contact:

Sudip Saha
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Logo: https://mma.prnewswire.com/media/713666/FactMR_Logo.jpg

© 2021 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.